3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Lymphoma, T-Cell, Cutaneous
6
Sezary Syndrome
5
Mycosis Fungoides
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Myeloproliferative Disorders
3
Multiple Myeloma
3
Lymphoma, T-Cell, Peripheral
3
Lymphoma, Non-Hodgkin
3
Lymphoma, Mantle-Cell
3
Lymphoma, Large-Cell, Immunoblastic
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, Follicular
3
Lymphoma, B-Cell, Marginal Zone
3
Lymphoma
3
Leukemia, Myeloid, Chronic-Phase
3
Leukemia, Myeloid, Acute
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Leukemia, Hairy Cell
3
Hodgkin Disease
3
Burkitt Lymphoma
3
Waldenstrom Macroglobulinemia
2
Recurrence
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Neuroblastoma
2
Melanoma
2
Lymphoma, Large-Cell, Anaplastic
2
Lymphoma, Extranodal NK-T-Cell
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
2
Immunoblastic Lymphadenopathy
2
Interventions
HhAntag691
25
Imiquimod
12
Biopsy
12
sonidegib
11
Aminolevulinic Acid
9
cemiplimab
8
Photochemotherapy
8
Nivolumab
8
methyl 5-aminolevulinate
7
Mohs Surgery
7
1-phenyl-3,3-dimethyltriazene
7
Tomography, Optical Coherence
6
Surgical Procedures, Operative
6
Specimen Handling
5
Radiotherapy
5
Itraconazole
5
pembrolizumab
4
daromun
4
Microscopy, Confocal
4
Magnetic Resonance Spectroscopy
4
Ipilimumab
4
Curettage
4
Standard of Care
3
Niacinamide
3
IPI-926
3
CTLA-4 Antigen
3
3-ingenyl angelate
3
tazarotene
2
talimogene laherparepvec
2
relatlimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Basal Cell
×
Alemtuzumab
×
Dermatologic
×
Clear all
NCT06705608
2024-11-26
MS; FTY720
University of British Columbia
Completed
4,000 enrolled